INBX - Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
2024-06-07 14:42:51 ET
Summary
- Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types.
- It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032.
- INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types.
- The global solid tumor therapeutics market is expected to reach $885.44 billion by 2033.
Inhibrx Biosciences, Inc. ( INBX ) is a biotech that should be on everyone's radar. The reason why I state that is because it was able to make significant progress relating to the development of a drug known as INBRX-101 for the treatment of patients with alpha-1 antitrypsin deficiency. With such remarkable progress made, plus the ability to advance this clinical candidate into a phase 3 study, it garnered interest from Sanofi ( SNY )....
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi